Amgen Inc. (AMGN) FY2026 Q1 P&L / Income Statement

Amgen Inc. (AMGN) FY2026 Q1 P&L / Income Statement

Income statement for 2026-01-01 through 2026-03-31. View: Product and service (18 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenues

8,618,000,000 US dollars

Cost of sales

2,744,000,000 US dollars

Gross profit (calculated)

5,874,000,000 US dollars

Operating expenses (calculated)

3,208,000,000 US dollars

Operating income

2,666,000,000 US dollars

Other income (expense), net (calculated)

negative 582,000,000 US dollars

Income before income taxes

2,084,000,000 US dollars

Provision for income taxes

265,000,000 US dollars

Net income

1,819,000,000 US dollars

Repatha

876,000,000 US dollars

Prolia

727,000,000 US dollars

EVENITY

562,000,000 US dollars

TEPEZZA

490,000,000 US dollars

Otezla

431,000,000 US dollars

BLINCYTO

415,000,000 US dollars

Nplate

412,000,000 US dollars

XGEVA

411,000,000 US dollars

TEZSPIRE

343,000,000 US dollars

Kyprolis

330,000,000 US dollars

ENBREL

320,000,000 US dollars

Aranesp

311,000,000 US dollars

Vectibix

287,000,000 US dollars

UPLIZNA

262,000,000 US dollars

IMDELLTRA/IMDYLLTRA

258,000,000 US dollars

KRYSTEXXA

255,000,000 US dollars

Other products

1,528,000,000 US dollars

Other revenues

400,000,000 US dollars

Selling, general and administrative

1,602,000,000 US dollars

Research and development

1,719,000,000 US dollars

Other

negative 113,000,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.